Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this internet live activity for a maximum of 21.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this internet live continuing medical education activity must complete the online CME Request for Credit Survey by Wednesday, September 30, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on this webpage and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 21.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
According to the latest data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program; Non-Hodgkin Lymphoma (NHL) is the seventh most common cancer in the United States with an estimated 74,200 new cases diagnosed in 2019. Just under 20,000 individuals were estimated to have died from NHL in 2019. Although lower in number than NHL, an estimated 8,110 new cases of Hodgkin Lymphoma (HL) were diagnosed in 2019, with approximately 1,000 deaths.
There have been increases in the five-year survival rates for both NHL and HL over the past fifty years. However, additional research and collaboration is needed in the detection, monitoring, and treatment of these diseases to both reduce the number of new cases, which has remained relatively flat, and to provide treatment options for patients with relapsed and/or refractory disease.
Lymphomas are an extremely heterogeneous set of cancers and understanding these differences holds promise for better therapeutics. The research being presented at this conference will address lymphoma precursor cells, analyze additional ways to classify lymphomas, review current therapies, explore opportunities for innovative clinical trial design, and prompt discussion of how to develop/optimize new therapeutics. The program was designed to take advances in basic research areas and discuss how those are being applied or have the potential to be applied for the betterment of patients in the clinic.
After participating in this CME activity, physicians should be able to:
- Articulate the potential advantages, challenges, limitations, and ways to optimize immunotherapy in the treatment of lymphoma.
- Identify ways in which lymphomas are classified.
- Explain the current state of CAR T-cell therapy in lymphoma.
- Evaluate the potential for biology-based clinical trials and provide rationale or support for this approach.
- Understand the challenges facing the implementation of liquid biopsies for disease monitoring and clinical decision making.
- Define the role of the epigenome in the development of lymphoma and how this knowledge can lead to novel therapies.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information is available below.
Acknowledgment of Financial or Other Support
The AACR gratefully acknowledges the following commercial supporters:
Professional Educational Grants
Questions about CME?
Please contact the Office of CME at (215) 440-9300 or [email protected].